Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LEMTRADA vs BEYFORTUS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Alemtuzumab is a humanized monoclonal antibody that binds to CD52, a protein expressed on the surface of mature lymphocytes (T and B cells) and to a lesser extent on monocytes, macrophages, and NK cells. Binding to CD52 induces antibody-dependent cell-mediated cytolysis and complement-mediated lysis, resulting in prolonged depletion of circulating lymphocytes.
BEYFORTUS (nirsevimab) is a recombinant human monoclonal antibody that binds to the prefusion conformation of the respiratory syncytial virus (RSV) F protein, inhibiting viral entry into host cells by blocking the fusion of the viral envelope with the host cell membrane.
Treatment of relapsing forms of multiple sclerosis (MS), for patients who have had an inadequate response to two or more drugs indicated for MS.,Treatment of B-cell chronic lymphocytic leukemia (B-CLL) (off-label in many regions due to regulatory changes).
Prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants entering their first RSV season, and in children up to 24 months of age who remain vulnerable through their second RSV season.
12 mg/day intravenously over 4 hours on 5 consecutive days (total 60 mg), followed by 12 mg/day intravenously over 4 hours on 3 consecutive days (total 36 mg) 12 months later.
Not applicable; BEYFORTUS (nirsevimab) is indicated for prevention of respiratory syncytial virus lower respiratory tract disease in neonates and infants. No adult dose exists.
12.7 days (range 7.7–22.1 days) after multiple doses; clinically relevant for prolonged lymphocyte depletion.
Terminal elimination half-life is approximately 26.8 days in infants, supporting season-long protection after a single dose.
Alemtuzumab is a monoclonal antibody; it is not metabolized by cytochrome P450 enzymes. Clearance occurs via intracellular catabolism and proteolytic degradation.
Nirsevimab is degraded via catabolic pathways into small peptides and amino acids.
Renal (primarily via catabolism to peptides and amino acids, minimal intact drug in urine). No specific biliary or fecal elimination data.
Beyfortus (nirsevimab) is eliminated primarily via catabolism to small peptides and amino acids. No specific data on renal or biliary excretion; expected to undergo proteolytic degradation with minimal renal or fecal elimination of intact drug.
Not determined; likely low due to monoclonal antibody nature (primarily binds to CD52 antigen).
Protein binding is approximately 99.5%, primarily to albumin.
Approximately 0.1 L/kg; indicates limited extravascular distribution, primarily in serum and lymphoid tissues.
Volume of distribution is approximately 4.5 L in infants (mean Vd ≈ 0.3 L/kg), indicating distribution primarily in plasma and interstitial fluid.
IV only; not applicable (100% bioavailability via IV infusion).
Bioavailability after intramuscular injection is approximately 70-80% (absolute bioavailability not established; relative to IV data).
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not recommended for severe renal impairment (Cr Cl <30 m L/min) due to lack of data.
No dosage adjustment required for renal impairment; nirsevimab is a monoclonal antibody not renally cleared.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not recommended in severe hepatic impairment (Child-Pugh C) due to lack of data.
No dosage adjustment required for hepatic impairment; nirsevimab is a monoclonal antibody not hepatically metabolized.
Safety and efficacy in pediatric patients (<18 years) have not been established.
Neonates and infants weighing <5 kg: 50 mg intramuscular (IM) single dose; infants weighing ≥5 kg: 100 mg IM single dose. Administer during RSV season.
No specific dose adjustment recommended; limited data available in patients ≥65 years; use with caution due to higher risk of infections and immune-mediated disorders.
Not indicated for geriatric population; no dosing recommendations available.
WARNING: SERIOUS AUTOIMMUNE CONDITIONS, INFUSION REACTIONS, AND MALIGNANCIES. Alemtuzumab can cause serious, potentially fatal autoimmune conditions (e.g., immune thrombocytopenia, glomerulonephropathies, autoimmune hemolytic anemia, autoimmune pancytopenia), infusion reactions, and an increased risk of malignancies including thyroid cancer, melanoma, and lymphoproliferative disorders. Only prescribers enrolled in a restricted distribution program should prescribe alemtuzumab.
No black box warning.
Autoimmune conditions: Monitor for immune thrombocytopenia, glomerulonephropathies, autoimmune hemolytic anemia, and autoimmune pancytopenia.,Infusion reactions: Premedicate and monitor; reactions can be severe.,Infections: Increased risk due to lymphopenia; monitor for Listeria, herpes, and other opportunistic infections.,Malignancies: Monitor for thyroid cancer, melanoma, and lymphoproliferative disorders.,Vaccination: Avoid live vaccines during and after treatment.,Reproductive risk: Advise women of childbearing age to use contraception during and for 4 months after treatment.
Hypersensitivity reactions including anaphylaxis have been reported.,Use caution in patients with thrombocytopenia or any coagulation disorder due to risk of bleeding from intramuscular injection.
Hypersensitivity to alemtuzumab or any of its excipients.,Active infection (except minor localized infections).,Known history of progressive multifocal leukoencephalopathy (PML).,Concurrent treatment with other immunosuppressive therapies (not recommended).
History of serious hypersensitivity reaction to nirsevimab or any component of the formulation.
No specific food interactions. Grapefruit and other CYP450 substrates are not relevant; alemtuzumab is not metabolized by CYP enzymes. Avoid alcohol due to potential immune effects.
No known food interactions. BEYFORTUS is administered by intramuscular injection and does not interact with dietary components.
Pregnancy category: Contraindicated in pregnancy. Alemtuzumab is an Ig G1 monoclonal antibody that crosses the placenta. First trimester: Fetal Ig G exposure begins around week 13 of gestation; prior to that, transfer is minimal. Second and third trimesters: Ig G actively transported across placenta, increasing fetal exposure. Cases of fetal harm (spontaneous abortion, fetal death) reported. Risk of profound lymphopenia and other immune alterations in the newborn. No adequate human studies; animal studies show embryolethality and developmental toxicity.
BEYFORTUS (nirsevimab) is a human monoclonal antibody against respiratory syncytial virus. There are no adequate and well-controlled studies in pregnant women. In animal reproduction studies, no adverse developmental effects were observed in pregnant rabbits or cynomolgus monkeys at doses up to 10 times the human clinical exposure. However, because monoclonal antibodies are transported across the placenta in increasing amounts as pregnancy progresses (especially in the third trimester), potential fetal exposure may occur. Based on limited data, the risk of major birth defects and miscarriage is unknown but expected to be low due to the Ig G1 nature and lack of known teratogenic signal.
Excreted in human milk in low amounts; M/P ratio not available. Given the high molecular weight (approx. 150 k Da) and potential for immunosuppression in the nursing infant, breastfeeding is not recommended during treatment and for at least 4 months after the last dose.
There are no data on the presence of nirsevimab in human milk, effects on the breastfed infant, or effects on milk production. Nirsevimab is a human monoclonal antibody (Ig G1) and is expected to be excreted into human milk in small amounts due to the high molecular weight and limited transfer via the neonatal Fc receptor. The M/P ratio has not been determined. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for BEYFORTUS and any potential adverse effects on the breastfed infant from the drug or underlying condition.
Contraindicated; do not use in pregnancy. No dosing adjustment studies exist. If a woman becomes pregnant during treatment, discontinue therapy immediately and refer to high-risk obstetrics. No pharmacokinetic data are available to suggest dose changes in pregnancy; however, altered volume of distribution and clearance may occur but are not characterized.
No dosing adjustments are required for BEYFORTUS during pregnancy. Pregnancy-related physiological changes (e.g., increased plasma volume, altered renal clearance) are not expected to significantly affect the pharmacokinetics of a monoclonal antibody administered intramuscularly, as nirsevimab has a long half-life and is not renally excreted. The standard single dose of 50 mg (for infants <5 kg) or 100 mg (for infants ≥5 kg) is recommended regardless of pregnancy status.
Lemtrada (alemtuzumab) is a CD52-directed cytolytic monoclonal antibody for relapsing-remitting multiple sclerosis (RRMS). Administer via IV infusion over 4 hours for 5 consecutive days (first course) and 3 consecutive days (second course, 12 months later). Premedicate with corticosteroids (e.g., methylprednisolone 1 g IV) for 3 days each course to mitigate infusion reactions. Monitor for autoimmune adverse effects: immune thrombocytopenia (ITP), thyroid disorders, nephropathies. Obtain baseline and monthly CBC, serum creatinine, urinalysis with microscopy, and thyroid function for 48 months after last dose. Vaccinate for varicella zoster virus (VZV) at least 6 weeks prior if seronegative; avoid live vaccines during and after treatment. Pregnancy category C—contraindicated in pregnancy; effective contraception required during and 4 months after treatment.
BEYFORTUS (nirsevimab) is a recombinant human monoclonal antibody for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants. It is administered as a single intramuscular injection, typically 50 mg for infants <5 kg and 100 mg for infants ≥5 kg. It is not a treatment for active RSV infection. It does not interfere with live attenuated vaccines; however, administration with other injectable vaccines at different sites is acceptable. Do not administer to infants with a history of severe hypersensitivity to nirsevimab or any excipients. Efficacy has not been established in infants with a history of RSV infection.
This drug is given as an intravenous infusion for five days in a row for the first course, and three days in a row one year later. Each infusion takes about 4 hours.,You will receive steroid medications before each infusion to reduce the risk of infusion reactions (fever, chills, rash, breathing problems).,Serious side effects include autoimmune conditions affecting blood cells (low platelets), thyroid, or kidneys. You need monthly blood and urine tests for at least four years after the last dose.,You may be at higher risk for infections; report any signs of infection (fever, cough, painful urination) immediately.,Do not receive live vaccines (e.g., chickenpox, nasal flu vaccine) during treatment and for at least 12 months after.
This vaccine is given as a single shot to prevent serious RSV disease in your infant.,It is not a treatment for active RSV infection; if your infant has RSV symptoms, inform the healthcare provider.,Common side effects include injection site reactions, rash, and fever. Contact your provider if these persist or worsen.,Inform the healthcare provider of any allergic reactions or bleeding disorders before administration.,Your infant can still receive other vaccines as scheduled.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LEMTRADA vs BEYFORTUS, answered by our medical review team.
LEMTRADA is a Monoclonal Antibody that works by Alemtuzumab is a humanized monoclonal antibody that binds to CD52, a protein expressed on the surface of mature lymphocytes (T and B cells) and to a lesser extent on monocytes, macrophages, and NK cells. Binding to CD52 induces antibody-dependent cell-mediated cytolysis and complement-mediated lysis, resulting in prolonged depletion of circulating lymphocytes.. BEYFORTUS is a Monoclonal Antibody for RSV Prophylaxis that works by BEYFORTUS (nirsevimab) is a recombinant human monoclonal antibody that binds to the prefusion conformation of the respiratory syncytial virus (RSV) F protein, inhibiting viral entry into host cells by blocking the fusion of the viral envelope with the host cell membrane.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LEMTRADA and BEYFORTUS depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LEMTRADA is: 12 mg/day intravenously over 4 hours on 5 consecutive days (total 60 mg), followed by 12 mg/day intravenously over 4 hours on 3 consecutive days (total 36 mg) 12 months later.. The standard adult dose of BEYFORTUS is: Not applicable; BEYFORTUS (nirsevimab) is indicated for prevention of respiratory syncytial virus lower respiratory tract disease in neonates and infants. No adult dose exists.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LEMTRADA and BEYFORTUS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LEMTRADA is classified as Category C. Pregnancy category: Contraindicated in pregnancy. Alemtuzumab is an IgG1 monoclonal antibody that crosses the placenta. First trimester: Fetal IgG exposure begins around week 13 of. BEYFORTUS is classified as Category C. BEYFORTUS (nirsevimab) is a human monoclonal antibody against respiratory syncytial virus. There are no adequate and well-controlled studies in pregnant women. In animal reproducti. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.